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WHO’s Global Programme to Eliminate Lymphatic Filariasis (LF) uses mass drug adminis-
tration (MDA) of anthelmintic medications to interrupt LF transmission in endemic areas.
Recently, a single dose combination of ivermectin (IVM), diethylcarbamazine (DEC), and
albendazole (ALB) was shown to be markedly more effective than the standard two-drug
regimens (DEC or IVM, plus ALB) for achieving long-term clearance of microfilaremia.
Objective and methods
To provide context for the results of a large-scale, international safety trial of MDA using tri-
ple drug therapy, we searched Ovid Medline for studies published from 1985–2017 that
reported adverse events (AEs) following treatment of LF with IVM, DEC, ALB, or any combi-
nation of these medications. Studies that reported AE rates by treatment group were
included.
Findings
We reviewed 162 published manuscripts, 55 of which met inclusion criteria. Among these,
34 were clinic or hospital-based clinical trials, and 21 were community-based studies.
Reported AE rates varied widely. The median AE rate following DEC or IVM treatment was
greater than 60% among microfilaremic participants and less than 10% in persons without
microfilaremia. The most common AEs reported were fever, headache, myalgia or arthral-
gia, fatigue, and malaise.
Interpretation
Mild to moderate systemic AEs related to death of microfilariae are common following LF
treatment. Post-treatment AEs are transient and rarely severe or serious. Comparison of AE
rates from different community studies is difficult due to inconsistent AE reporting, varied
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infection rates, and varied intensity of follow-up. A more uniform approach for assessing and
reporting AEs in LF community treatment studies would be helpful.
Author summary
WHO’s Global Programme to Eliminate Lymphatic Filariais (LF) supports annual mass
drug administration to over 400 million people in LF-endemic areas each year. Two drug
combinations (either DEC or ivermectin, given with albendazole) have been recom-
mended in most endemic areas. With the exception of well-described serious adverse
events (AEs) occurring in patients with high level loiasis, severe AEs due to these medica-
tions are extremely rare. Mild to moderate AEs, however, are common, particularly in
patients with active filarial infection. In this manuscript we synthesize published data on
AEs following single-dose treatment of LF with ivermectin, DEC, or albendazole. This
provides a background against which to compare the safety of triple drug therapy (iver-
mectin, DEC, and albendazole) recently endorsed by WHO, and provides a useful context
for evaluating safety of new treatments for LF. The compiled data illustrate that transient,
mild to moderate AEs following single-dose LF treatment are common in microfilaremic
patients and are much less common in amicrofilaremic patients. They also show that pas-
sive surveillance for post-treatment AEs underestimates AE incidence and suggest that
adherence to common reporting standards would improve the usefulness of AE reporting
in filariasis studies.
Introduction
Infection with the filarial nematode parasites Wuchereria bancrofti, Brugia malayi, or Brugia
timori is known as lymphatic filariasis (LF). These infections cause severe, disabling conditions
including lymphedema, elephantiasis, and hydroceles in tens of millions of people in tropical
and subtropical countries. Annual mass drug administration (MDA) coordinated by WHO’s
Global Programme to Eliminate LF (GPELF) has significantly reduced LF transmission in
many of the 78 initially endemic nations [1–3]. Yet LF remains far too common, with tens of
millions infected and 850 million people at risk of acquiring the infection in 53 countries [3].
With approximately 500 million people receiving MDA for LF each year, understanding,
anticipating, and preparing the targeted population for MDA-related adverse events (AEs) is
important for program success.
Medications used for MDA include diethylcarbamazine (DEC), ivermectin (IVM) and
albendazole (ALB). The combination of IVM plus ALB is used in areas of Africa where oncho-
cerciasis (river blindness) is co-endemic with LF. Twice yearly ALB alone is recommended for
LF-endemic areas of Africa that are co-endemic for loiasis, and DEC plus ALB is used in the
rest of the world. Serious (life-threatening) AEs due to MDA are exceedingly rare [4–7]. How-
ever, when they do occur they can profoundly impact the treated community and jeopardize
program success [8]. When communities are well-informed about the type and severity of AEs
to be expected, they may be less likely to avoid MDA out of fear of AEs. Furthermore, the
knowledgeability of community health workers (drug distributors) can be a major determinant
of MDA adherence [8]. A clear understanding of the nature of expected AEs should empower
program managers and community health workers to prepare their communities to anticipate
and accept transient AEs, which may in turn improve compliance with MDA and facilitate LF
elimination efforts.
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A promising new combination therapy for LF that combines a single dose of IVM, DEC,
and ALB (IDA) appears to be highly effective [9], and its safety is has been evaluated in large
community-based studies in several locations (ClinicalTrials.gov Identifier: NCT02899936)
[10]. This manuscript’s purpose is to provide context for understanding the safety of the new
IDA treatment by reviewing published data on the rates and nature of AEs following single-
dose treatment for LF with any of the IDA medications. As previously noted by many others,
AE reporting in LF treatment trials is highly variable and potentially affected by multiple fac-
tors including blood microfilaria (Mf) counts, treatment regimens, filarial species, population
demographics, and importantly, the thoroughness of post-treatment surveillance. We there-
fore sought to review AE data from published LF treatment studies to further understand the
effect of these parameters on AE rates and severity. Our objective was to evaluate reports of
AEs following single dose LF treatment of children and adults with IVM, DEC, or ALB (either
as monotherapy or in multidrug combination regimens), published since 1985. In this report
we first present a broad summary of the literature reviewed and then a quantitative synthesis
of published AE rates from studies meeting our specified inclusion criteria.
Methods
The primary outcome of interest for the quantitative synthesis was the proportion of partici-
pants experiencing at least one AE (aggregate AE rate). Rates of individual AEs were a second-
ary outcome. We did not use a pre-specified AE definition, but rather accepted all AEs
reported by the authors of the individual studies. In this manuscript we classify AEs as mild if
they do not interfere with normal daily routine (work or school), as moderate if they interfere
with daily routines (work or school) but not with activities of daily living, and as severe if they
interfere with activities of daily living or cause temporary incapacitation. These designations
correspond to Common Terminology Criteria for AEs grades 1 (mild), 2 (moderate), and 3
(severe). Serious AEs are those that are life-threatening or result in hospitalization or perma-
nent injury (grade 4) or are fatal (grade 5) [11].
Literature search
We reviewed AE data from studies of LF treatment with single-dose regimens that were pub-
lished between 1985 and 2017. We searched Ovid Medline and Embase for any articles with
Medical Subject Headings (MeSH) terms “Elephantiasis, Filarial” and “Drug Therapy” plus
any of the following terms: “Adverse Events”, “Poisoning”, or “Toxicity”. We limited our
search to English or French language manuscripts dealing with human infections. The most
recent search was conducted on 21 Aug, 2017. Two authors (PB and CH) reviewed each publi-
cation and gathered additional pertinent publications from articles referenced therein. Publi-
cations with sufficient AE data were selected for a quantitative analysis of AEs as described
below. We did not pre-specify nor register a review protocol. We did not attempt to contact
authors to identify additional studies.
Selection of studies for quantitative analysis
Studies published after 1985 that reported AE rates following single-dose LF treatment with
IVM, DEC, or ALB (alone or in combination) were included. Studies dealing with multi-day
courses (generally of DEC) were reviewed, but excluded from the quantitative analysis, as were
studies that either provided inadequate information on AEs by treatment arm or did not con-
duct AE surveillance within one week following treatment. Complete inclusion and exclusion
criteria are shown in Table 1. We followed the PRISMA Statement for Reporting Systematic
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PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006454 May 16, 2018 3 / 22
Reviews and Meta-Analysis [12]; the completed PRISMA checklist is available as a supplemen-
tal file (S1 Table).
Quantitative synthesis
From studies meeting inclusion criteria we extracted data including: study location (country),
age range and gender of participants, intensity of surveillance, treatment regimen, Mf preva-
lence, geometric mean Mf counts, presence of co-infections, overall rate of AEs, and rates for
any specific AEs reported. For studies that reported AEs following multiple MDA treatment
rounds, we included only the AE rates that occurred after the first treatment. For studies in
which one but not all treatment arms met inclusion criteria (for example, when single dose
IVM or DEC was compared to 12 days of DEC), we included data only from the arm(s) meet-
ing inclusion criteria. The number of participants reported in our analysis is the number for
whom AE surveillance was conducted, which was sometimes lower than the total number
treated. For example, one study conducted active post-MDA surveillance within a subset of
483 persons among 8 million people treated [18]; in our analysis, the N for this study was 483.
All extracted data were analyzed using Stata version 12.1 (College Station, TX). Because the
data were not normally distributed, we report means and interquartile ranges (IQR) and use
boxplots for graphical representation. Since AE reporting was insufficiently uniform among
included studies, we did not attempt a formal meta-analysis of AE rates, nor did we attempt
statistical analyses. Rather, we sought to present a graphical synthesis of data from these dispa-
rate studies to illustrate the range of data and an estimate of central tendency (median and
interquartile range). To assess for reporting bias in individual studies, we stratified surveillance
for AEs in each study as active (individual participants were contacted and asked about AEs)
or passive (individuals with AEs had to seek out the study team to report). The quality of active
surveillance was further categorized as “high” (at least daily contact during the first 72 hours),
“moderate” (at least one contact within first 72 hours), or “low” (participants contacted after
72 hours). Although we hoped to analyze the effect of each extracted variable on reported AE
rates, we found that the quality of data reported for most parameters was insufficient. We
therefore limited our analysis to an ad hoc comparison of treatment regimens, Mf status, and
intensity of AE surveillance.
Results
Literature review
Many informative articles that reported AEs following treatment for LF could not be included
in our quantitative analysis either because they reported composite AE scores rather than
rates, or because they did not report AE rates separately by treatment group. We have
Table 1. Inclusion and exclusion criteria for quantitative analysis.
Inclusion Criteria Exclusion Criteria
• Treatment with DEC, IVM, or ALB
• Report AE rates by study arm
• AE data collected within first week after
treatment
• Published between 1985 and 2017
• Study arms with 10 participants
• Studies of multi-dose treatments
• Adverse event assessments conducted long after treatment
• Co-infection with Onchocerca volvulus or Loa loa
• Treatment with other antifilarial medications (i.e. doxycycline)
• Co-administration of other medications (such as azithromycin
or praziquantel)
We included studies that used a preliminary clearing dose [13–16] or when a “single dose” treatment was split over
two days [17].
https://doi.org/10.1371/journal.pntd.0006454.t001
Adverse events following treatment of lymphatic filariasis
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006454 May 16, 2018 4 / 22
attempted to review some of the observations from both included and excluded publications
in the following paragraphs.
LF MDA medications. Diethylcarbamazine (DEC). DEC is a piperazine derivative with
microfilaricidal and partial macrofilaricidal activity [19], and the amount traditionally given
for LF treatment was 72 mg/kg divided in 12 daily doses. Although some early studies sug-
gested that weekly or monthly treatments might be equally or more effective than the 12 day
treatment course [20, 21], it was not until single dose IVM was shown to drastically reduce Mf
counts that single dose DEC was tested and found to be effective [16, 22–24]. A 6mg/kg DEC
dose appears to have the best balance between efficacy and AEs [22]. Mf counts drop markedly
in the first few days following single-dose DEC with continued slow decline for 6 or 7 months.
This decline is generally followed by partial rebound of microfilaremia [16, 24–30]; the level to
which Mf counts rebound may be lower with higher cumulative DEC doses [19, 31–36]. Seri-
ous AEs including loss of vision and fatal encephalopathy can occur when DEC is given to per-
sons with active onchocerciasis or loiasis [37]. DEC is therefore not used in areas of Africa
where LF is co-endemic with O. volvulus or L. loa. Direct pharmacologic AEs in persons with
no filarial infections are generally limited to transient gastrointestinal upset (nausea, vomiting,
diarrhea), dizziness, or lightheadedness that occur within a few hours of ingestion [19, 38].
Ivermectin (IVM). IVM is a semisynthetic member of the avermectin class of antihel-
minthics initially isolated from fermentation products of Streptomyces avermitilis. IVM treat-
ment for LF was first reported in the late 1980s [39–41] and 15 early safety and efficacy studies
of IVM for bancroftian filariasis were reviewed in a 1997 meta analysis [42]. IVM dosing for
LF MDA is based on height and roughly corresponds to 150–200 μg/kg. Single dose IVM
induces a rapid clearance of circulating Mf within the first five days; rebound of microfilaremia
following IVM begins as early as 30 days post-treatment with continued increases out to 6
months [16, 25, 40, 41, 43–46]. This rapid Mf clearance occurs with doses as low as 20 μg/kg
[15, 39, 46], but higher doses (200 to 400 μg/kg) may have a more prolonged effect [47]. Unlike
DEC, single dose IVM has little or no effect on filarial antigen levels [48–50], suggesting a lack
of macrofilaricidal effect. IVM is teratogenic at repeated high doses in laboratory animals and
is not given to children weighing less than 15 kg or to pregnant women during MDA for LF [2,
51]. As with DEC, IVM can precipitate severe encephalopathy and death when given to per-
sons heavily infected with L. loa [52, 53], and is not used as MDA for LF in areas with high
intensity L. loa infections.
Albendazole (ALB). ALB belongs to the benzimidazole group of anthelminthic agents and
is thought to inhibit tubulin polymerization leading to immobilization and death of susceptible
helminths. Two meta-analyses of ALB combination therapy for LF published in 2005 disagreed
regarding ALB’s value for treating LF [6, 7], and its inclusion in LF MDA regimens is partially due
to its activity against soil-transmitted helminths (STH) [6, 7, 54]. Single-dose ALB alone induces
very slow declines in Mf counts and a minor decrease in filarial antigen levels, suggesting a partial
macrofilaricidal effect [54–56], which may be enhanced by twice yearly treatment [57, 58].
Although high dose ALB (400 mg twice daily) for 3 weeks induced scrotal reactions in 11 of 15
men in one study (compared to zero of 13 DEC-treated men) [59], there is no evidence that add-
ing single-dose ALB to IVM or DEC for LF MDA increases AEs [5]. In areas where LF is co-
endemic with loiasis, semiannual ALB alone (together with integrated vector management) is rec-
ommended for LF MDA, because ALB can be safely given to persons with loiasis [60, 61].
AEs following treatment of LF. Transient mild to moderate adverse reactions such as
fever, headache, dizziness, malaise, myalgia, fatigue, and gastrointestinal upset are common
after treatment of LF and are primarily related to dying Mf [5, 6, 62]. Less commonly reported
AEs include cough and dyspnea [15, 17, 23, 40] (sometimes associated with blood-tinged spu-
tum and transient pulmonary infiltrates [63] or bronchoconstriction [40, 64]), urticaria or
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other rash [45, 63, 65], transient proteinuria or hematuria [9, 44, 63, 66], elevated alkaline
phosphatase [63] or transaminase levels [46, 59, 65], palpebral edema (with DEC) [17],
increased eosinophilia 7–14 days post-treatment [17, 40, 59, 67], and postural hypotension
[16, 23, 40, 45, 68]. Systemic AEs generally occur with 24–48 hours after the first dose of
microfilaricidal medications (IVM or DEC) [23, 24, 29, 30, 40, 43–45, 54, 56, 64, 67–75],
including when low “clearing doses” of drugs are given before full therapeutic doses [14, 15,
24]. Most systemic AEs resolve within 48 hours of onset, although they sometimes last longer
[15, 16, 24, 29, 30, 40, 44, 45, 54, 56, 64, 67, 69, 73, 75].
Localized AEs following LF treatment are much less common than systemic AEs. They
include the development of subcutaneous or scrotal nodules, spermatic cord swelling, new
onset or increased hydrocele, dilated and inflamed lymphatic vessels (the “string sign”) [68],
arthritis, lymphadenitis (sometimes with suppuration), and new onset lymphedema [76].
Local reactions may occur within 24–48 hours after treatment, but often the onset is later (1
week or more after treatment) [15, 17, 44, 45, 55, 59, 66, 72, 77]. They are generally self-limited,
resolving over the course of one to several weeks. They are thought to be caused by the death
of adult filarial worms in lymphatic vessels [14, 15, 17, 19, 44, 63, 78, 79]; prior to the develop-
ment of adult worm antigen assays and ultrasound visualization of adult worms [79], rates of
scrotal reactions were frequently used as a surrogate measure of macrofilaricidal activity [15,
59, 77]. Biopsies of scrotal nodules confirm the presence of dead or dying adult worms and
excised nodules sometimes contain both dying and healthy adult worms [79–81].
Factors potentially affecting reported AE rates. Infection intensity. Because AEs are
related to the death of circulating Mf, the rates and severity of AEs following LF treatment
increase with increasing Mf loads and increased microfilaricidal efficacy [14–16, 22, 30, 34, 38,
39, 43, 47, 54, 65, 78, 82–84]. Because of this, AEs are highest following the first dose of micro-
filaricidal drugs, and they tend to be less frequent and milder in later treatment rounds [47, 67,
74, 77, 85–89]. One notable exception was an initial dose-finding study of IVM against brugian
filariasis that did not observe a correlation between AEs and pre-treatment Mf counts [67].
Gender and age. Most studies that reported gender-specific rates of directly-observed AEs
did not report significantly different rates between men and women [15, 22, 30, 56, 90, 91].
However, two community MDA studies with passive AE surveillance reported higher rates in
women. This may reflect gender-specific differences in reporting, rather than physiologic dif-
ferences [76, 92]. In one large MDA study in Haiti, moderate AEs (those interfering with
school or work) were more frequently reported by men, and these were most commonly due
to scrotal pain [72]. Reported AE rates tend to be lower in children [48, 49, 54, 64, 84].
Species differences. Differences in susceptibility to treatment between brugian and bancrof-
tian filariasis may affect AE rates among those who are Mf positive. For bancroftian filariasis,
IVM appears to clear Mf more rapidly and more completely than DEC [14, 16, 17, 25, 30, 45,
93, 94], but Mf counts also rebound sooner following IVM treatment. DEC induces a slower,
more sustained decline, with gradual Mf reductions out to about 6 months [25, 31, 64, 95].
Over a longer period, reductions in Mf counts are equivalent [14, 25, 71, 96, 97] or slightly bet-
ter with DEC [16, 17, 24, 45]. For bancroftian filariasis, acute reactions tend to be higher with
IVM and later (localized) reactions higher with DEC [17, 45].
The decline in Mf counts following IVM treatment may be somewhat slower in persons
with brugian filariasis [65, 67] and AEs following IVM treatment of brugian filariasis may be
less severe and occur slightly later post-treatment (day 2–3) [65]. Brugia Mf may be more sen-
sitive to DEC-mediated killing [19, 24, 68, 82], and Brugia Mf carriers may have more AEs
when treated with DEC than W. bancrofti Mf carriers [24, 73, 82]. Treatment of brugian filaria-
sis does not result in scrotal reactions, a finding that reflects Brugia’s lack of tropism for scrotal
lymphatic vessels and the lack of hydroceles in brugian filariasis [24].
Adverse events following treatment of lymphatic filariasis
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Medication dose. The initial evaluation of IVM for bancroftian filariasis suggested that
25 μg/kg worked as well as higher doses, but with fewer AEs [40]. The initial study of IVM for
brugian filariasis also had a trend towards lower AEs with 25 μg/kg, but this was not statisti-
cally significant [67]. In general, however, the level of microfilaremia is much more predictive
of AEs than the dose of antifilarial medication [39, 84]. For example, in several studies where
low “clearing doses” of medications were given prior to higher “treatment” doses, AE rates
were higher with the clearing dose than with the treatment dose for both IVM [13, 15, 98] and
DEC [98].
Passive vs. active surveillance. Intensity of AE surveillance following MDA can have a large
effect on reported AE rates. One study directly compared AE rates reported by active surveil-
lance (daily visits) with AE reports from subsequent coverage surveys and found 3–4 fold
higher AE rates identified by active surveillance [18]. In passive surveillance studies, the rate of
reported symptoms may have more to do with general health-seeking behavior than with Mf-
related AEs [99].
Co-infections. Co-infections with other filarial species can have dramatic effects on AEs
experienced following treatment for LF. These include the well-recognized risk of ocular dam-
age with visual loss after treatment of onchocerciasis with DEC, and encephalopathy and death
in persons with heavy loiasis infections [52, 53]. GI symptoms following MDA for LF may be
partially related to the effects of treatment on intestinal helminths; extremely low rates of GI
side effects were observed in one study that excluded those with a positive stool ova and para-
site screen from treatment [56].
AE pathogenesis. Wolbachia. The molecular mechanisms underlying AEs following LF
treatment are incompletely understood, but one leading hypothesis is that they are related to
release of bacterial endotoxin-like lipoproteins from endosymbiotic Wolbachia released from
dying Mf. Several lines of evidence support this hypothesis. First, B. malayi-infected adults
with moderate to severe AEs were more likely to have Wolbachia DNA in post-treatment
serum samples compared to those with mild or no AEs [100]. Second, a lipopolysaccharide
(LPS)-like activity in B. malayi extract is a potent inducer of TNF-α, IL-1ß and nitric oxide
(NO) in murine macrophages, while extracts from the rodent filarial parasite A. viteae (which
do not harbor Wolbachia) do not induce these responses [101, 102]. It was surprising, there-
fore, when the B. malayi-associated Wolbachia genome published in 2004 did not contain
genes required for the biosynthesis of lipid A, an essential component of LPS [103]. This sug-
gested that Wolbachia does not contain LPS in its cell wall [104]. However, a peptidoglycan-
associated lipoprotein (PAL) in Wolbachia may effectively mimic the activity of LPS. PAL can
signal through TLR2/TLR6, induces pro-inflammatory responses in vitro (in murine and
human cells) and in vivo (mice) [105], and is abundant in B. malayi, where it localizes to the
Wolbachia membrane [106]. Finally, depletion of Wolbachia with a three or six week treatment
course of doxycycline prior to anti-filarial treatment with ALB plus either DEC or IVM
decreased the risk of acute AEs [107, 108]; whether this was due to depletion of Wolbachia or
to doxycycline-related reductions in Mf counts is unclear. Concurrent treatment with doxycy-
cline and DEC reduced inflammatory cytokines and AE severity among microfilaremic
patients in another study [109], but an imbalance in the baseline Mf counts in the latter study
makes that finding difficult to interpret. Another study did not demonstrate a significant
reduction in AEs in persons with LF after pre-clearance of Wolbachia with doxycycline [110].
Circulating immune complexes. Circulating immune complexes may also contribute to the
development of AEs following LF treatment. These are heterogeneous aggregates of antigens,
antibodies and components of the complement cascade [111] that activate pro-inflammatory
pathways when they circulate or accumulate in tissue. One publication reported that filarial
excretory-secretory antigens and immune complex titers increased after DEC treatment of LF
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patients [112]. A later study showed that these changes were temporally correlated with the
onset of AEs and that their magnitude was significantly greater in individuals who developed
AEs after treatment [113].
Quantitative synthesis of published AE rates
To summarize published rates of AEs following single-dose treatment of LF, and to explore
how these might differ by treatment medication and AE surveillance, we compiled data from
articles with adequate AE reporting into a combined analysis. Among 162 full text articles
reviewed, 55 contained AE data that met criteria for inclusion (Fig 1). There was considerable
heterogeneity in the way that AEs were reported in these studies; 34 reported both the aggre-
gate incidence of AEs (i.e. the number of persons experiencing any AE) and the percentage of
persons experiencing specific AEs. Seventeen studies reported an aggregate incidence but not
specific events, and four reported specific events but not aggregate incidence. Methods of AE
ascertainment varied widely between studies, from intensive in-hospital monitoring to passive
reporting in community-based trials. For the purposes of our analyses we grouped the studies
into two main types: (1) clinical trials with active AE surveillance and (2) community studies
with either active or passive surveillance. The former group comprises studies in which 100%
of participants were Mf positive, while community studies had varied Mf rates (Table 2).
AE rates by Mf status and surveillance intensity. As shown in Fig 2, reported AE rates
were markedly higher in study arms where 100% of participants were Mf positive. The median
aggregate AE rate (proportion of participants experiencing at least one AE) among study arms
Fig 1. PRISMA flow diagram for inclusion of articles in the quantitative synthesis.
https://doi.org/10.1371/journal.pntd.0006454.g001
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where all participants were microfilaremic was 70% when each study was given equal weight
and 67% when results were adjusted to consider the number of participants per study arm.
Reported AE rates in non-placebo groups with no microfilaremia ranged from zero to 37%
with a median of 8.3% (7.1% when adjusted for participants per study arm). As expected, stud-
ies with passive surveillance reported much lower AE rates (ranging from 0 to 24% regardless
of Mf prevalence); this included two study arms from one study in which all participants were
microfilaremic [127]. A complete list of the studies included with the extracted data and notes
is available as a supplement (S2 Table).
AE rates by treatment. Aggregated AE rates by treatment regimen from studies with
active surveillance are shown in Fig 3. AE rates in amicrofilaremic groups were less than or
equal to 10% in all groups except among persons treated with DEC only. Among the five
included amicrofilaremic treatment groups receiving DEC, three were from a single study that
compared different DEC doses (4, 6, or 8 mg/kg) and reported AE rates >25% with all three
DEC doses [22]. It is difficult to explain the unusually high AE rates reported from that study.
Table 2. Articles included in the quantitative analysis by article type and study location.
Study location N Studies N participants References
Hospital or Clinic Based Studies with High Quality, Active Surveillance
Brazil 3 194 [17, 44, 64]
China 1 60 [71]
Egypt 1 71 [45]
French Polynesia 7 314 [69, 85, 90, 93, 94, 114, 115]
Haiti 4 340 [13, 15, 54, 84]
India 11 591 [16, 30, 40, 43, 56, 67, 68, 75, 87, 116, 117]
Indonesia 1 15 [23]
Malaysia 1 40 [65]
Papua New Guinea 1 24 [9]
Senegal 1 16 [41]
Sri Lanka 2 77 [14, 46]
Tanzania 1 25 [118]
Subtotal 34 1,767
Community Based Studies with Active Surveillance
Brazil 2 818 [76, 119]
Egypt 1 28 [77]
French Polynesia 2 4,421 [39, 47]
Ghana 2 1,299 [108, 120]
India 5 10,596 [18, 86, 110, 121, 122]
Papua New Guinea 1 966 [123]
Samoa 1 458 [22]
Sri Lanka 1 31 [29]
Tanzania 1 57 [124]
Subtotal 16 18,674
Community Based Studies with Passive Surveillance
Ghana 1 15,020 [125]
Haiti 2 74,968 [72, 99]
Kenya 1 170 [126]
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Aggregate AE rates after treatment of microfilaremic persons with regimens that included
DEC or IVM ranged between 40 and 100%, with two exceptions: Dunyo reported AE rates of
25.8% and 36.3% among those treated with IVM alone or IVM plus ALB, respectively [120],
and Mak reported a rate of 27.5% among those receiving IVM alone [65]. Among the three
included studies reporting aggregate AE rates after ALB only treatment, AEs were reported in
11% of 80 participants (tactile fever, myalgia, headache, weakness, abdominal pain, itching)
[120], 38% of 12 participants (itching, palpitation, or fever) [118], and 42% of 19 participants
(predominantly fever and myalgia) [56].
Rate of specific AEs. Results varied widely in studies with active surveillance that reported
specific AEs after treatment of Mf positive persons. Rates of fever were 100% in some studies,
and other systemic symptoms including myalgia/arthralgia, dizziness, giddiness, weakness,
fatigue, and malaise were also very common. Rates of systemic events in amicrofilaremic indi-
viduals were much lower (Fig 4). The rates and patterns of AEs did not clearly differ between
DEC and IVM, but AEs were much less common after ALB, and they were low with any medi-
cation in amicrofilaremic participants (Fig 5).
Fig 2. Box plot of reported percentage of participants experiencing at least one AE among individual treatment
groups (study arms), comparing active (dark boxes) and passive (light boxes) surveillance methods, excluding
placebos. Groups where no participants (0%) or all participants (100%) were Mf positive were from hospital or clinic-
based clinical trials; those with “varied” Mf status were from community studies. A) Results when each study group
was considered to have equal weight. B) Results when results were adjusted to consider the number of participants in
each study group. Boxes indicate the interquartile range (IQR) and dashed line the median. Whiskers indicate the
upper and lower adjacent values: upper = the greatest value less than (75th percentile + (1.5 x IQR)); lower = the lowest
value greater than (25th percentile–(1.5 x IQR)).
https://doi.org/10.1371/journal.pntd.0006454.g002
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Discussion
In this review we initially sought to quantify the effects of various factors on AE rates that
occur following MDA for LF. We quickly realized that the heterogeneity in the way AEs have
been reported in the literature would not allow a meaningful quantitative multivariate analysis.
We nevertheless felt a compilation of reported AE rates would be beneficial. Despite the limita-
tions of combining data from methodologically disparate studies, we believe the compiled data
illustrate the following main points: 1) AEs are very common in microfilaremic patients after
single-dose treatment of LF with drugs (IVM and DEC) that rapidly reduce Mf counts. 2) AEs
are much less common in amicrofilaremic participants, regardless of treatment regimen. 3)
Passive surveillance tends to underestimate the occurrence of AEs, and 4) Heterogeneity in the
stringency of AE surveillance and format of AE reporting makes comparisons between studies
difficult.
The relationship between AE rates and the prevalence of microfilaremia is illustrated by the
striking differences between study arms with 100% microfilaremia and those with no microfi-
laremia. It would have been interesting to compare Mf prevalence to AE rates among the com-
munity studies with varied Mf prevalence; this was not attempted because of the variability in
AE reporting for these studies and because uncertainty regarding true Mf rates would have
made this comparison unreliable.
Fig 3. Percentage of participants experiencing at least one AE in studies with active surveillance, according to the microfilaremia (Mf) status of participants.
Groups where no participants (0%) or all participants (100%) were Mf positive were from hospital or clinic-based clinical trials; those with “varied” Mf status were from
community studies. The top panels show equal weighting for each study, regardless of participant number; results in the bottom panels are weighted by participant
number. Boxes indicate the interquartile range (IQR) and dashed line the median. Whiskers indicate the upper and lower adjacent values: upper = the greatest value less
than (75th percentile + (1.5 x IQR)); lower = the lowest value greater than (25th percentile–(1.5 x IQR). Abbreviations: ALB = Albendazole, DA = DEC + Albendazole,
DI = DEC + Ivermectin, IA = Ivermectin + Albendazole, IDA = Ivermectin + DEC + Albendazole, IVM = Ivermectin.
https://doi.org/10.1371/journal.pntd.0006454.g003
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It is clear that community proclivities for reporting AEs vary from place to place and study
to study. This is perhaps most evident in reported AE rates after placebo treatment. Studies
with highly active AE surveillance in Haiti and Tahiti reported high AE rates after placebo
treatment [54, 84, 93], but AE rates were low after placebo treatment in Ghana and India [86,
120]. This place-to-place AE reporting variability is also evident in the wide range of AE rates
reported among different studies with the same treatment regimens (see Figs 3 and 5). Poten-
tial reasons for this might include the prevalence of STH or other helminth infections, differing
intensities of LF infection, and varying cultural norms. In addition, where populations have
been sensitized to expect AEs following MDA, more AEs may be perceived [18].
Nearly all the studies cited in this review reported AE rates in some manner, but we were
only able to include 55 in the quantitative synthesis. The primary reason for excluding studies
was that they did not present AE data in a way that linked AE rates to treatment regimens. For
example, many studies reported AE severity scores rather than rates. Others reported that AE
rates did not differ significantly between treatment groups, but did not report the numbers for
each group. When AE rates were reported by treatment group, comparisons were often ham-
pered by non-standardized AE reporting procedures. Some authors did not report the time-
frame over which AE surveillance was conducted, making it difficult to surmise whether early
or late AEs may have been missed. Although most studies included in our analysis described
whether AE surveillance was active or passive, many contained insufficient detail to determine
how sensitive the study procedures were for detecting AEs. For example, ascertainment rates
Fig 4. Reported percentages of specific AEs in treatment arms with 100% microfilaremia rates (shaded bars) or no
microfilaremia (open bars). Only studies with active AE reporting are included and each study arm is given equal
weight (not weighted by participant number). Boxes indicate the interquartile range (IQR) and dashed line the
median. Whiskers indicate the upper and lower adjacent values: upper = the greatest value less than (75th percentile +
(1.5 x IQR)); lower = the lowest value greater than (25th percentile–(1.5 x IQR)).
https://doi.org/10.1371/journal.pntd.0006454.g004
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(the proportion of participants in community-based studies who were actually visited and que-
ried about AEs) were almost never reported.
This review has several strengths and weaknesses. The primary strength is that it compiles
data from 30 years of published studies. It also illustrates how variable AE reporting can be,
and it provides a context for interpreting AE rates observed in future LF treatment studies.
One weakness was our inability to include data from many high quality studies that did not
report AEs by treatment arm. In addition, because we restricted our analysis to studies of sin-
gle-dose therapy, many rich and highly informative studies that used multi-dose treatment
regimens were excluded. In general, the pattern of AEs reported in such studies was similar to
single dose studies. That is to say, the rate and severity of AEs increased with increasing Mf
counts and most AEs occurred during the first 48 hours after the initial treatment dose
[38, 82].
The heterogeneity in AE reporting among the reviewed studies highlights the need for a
more structured approach to AE reporting in LF treatment studies. Although this problem is
not unique to filariasis [128], it can be compounded by the nature of community-based
Fig 5. Percentage of participants experiencing common systemic AEs by treatment group, according to the microfilaremia status of participants. DEC and IVM
data include all study arms where the indicated drug was given alone or in combination (with or without ALB). For clarity, the ALB panel shows only study arms in
which ALB alone was given. The upper panels assign each study are equal weight; the lower panels are weighted according to number of participants per study arm.
Boxes indicate the interquartile range (IQR) and horizontal line the median. Whiskers indicate the upper and lower adjacent values: upper = the greatest value less than
(75th percentile + (1.5 x IQR)); lower = the lowest value greater than (25th percentile–(1.5 x IQR)).
https://doi.org/10.1371/journal.pntd.0006454.g005
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studies. We therefore suggest the following measures for improving AE reporting in commu-
nity based treatment trials for LF and other neglected tropical diseases (Box 1). 1) Clearly
specify the methods for ascertaining AEs. Indicate whether an attempt was made to contact
each participant (active surveillance) or whether participants were required to seek out study
staff to report AEs (passive surveillance). Indicate when and how often participants were con-
tacted. Avoid ambiguous language such as “followed closely”, or “closely monitored”. Rather,
describe what was actually done. For example, “treated individuals were visited daily in their
homes for five days after treatment”. 2) If surveillance was active, report the ascertainment
rate; that is, the proportion of participants sought during surveillance that was actually found.
Knowing what proportion of participants actually contributed to the reported AE rates will
help the reader assess the reported findings. For example, one study reported, “All subjects
[were] asked to come to the study site on day 2 and day 5. . ..In addition, team members also
went door to door.” The door to door contacting was presumably meant to ascertain AEs in
subjects not reporting at the study site, since subjects may choose not to present for follow-up
either because they feel well and see no need, or because they feel ill and don’t wish to leave
their homes. The higher the proportion of participants for whom actual AE status is not ascer-
tained, the greater the uncertainty regarding the reported AE rates. Unfortunately, the study
cited—and most other community studies we reviewed—did not report ascertainment rates.
3) Report numerators and denominators. When severity scores are used (for example,
1 = mild, 2 = moderate, 3 = severe) to compare AEs between study groups, the actual number
of persons experiencing AEs should also be reported so that rates can be calculated. The differ-
ence between one person with a severe AE and three people with one mild AE each is impor-
tant, and the reporting of AE data should allow the reader to distinguish the difference. In
addition to clearly specifying the number of persons experiencing AEs (the numerator), the
denominator should be clearly defined. In active studies, we suggest reporting AE rates as the
proportion of those experiencing AEs over the number actually assessed. For example, five
persons experiencing AEs among 20 patients treated should be reported as 50% (not 25%) if
Box 1. Recommendation for AE reporting in filariasis studies.
• Clearly specify the method for ascertaining AEs.
 Was an attempt made to contact each participant to assess for AEs?
 When and how often were AEs assessed?
• Report the ascertainment rate (the percentage of participants assessed for AEs).
• Report numerators and denominators.
 How many adverse events occurred among how many participants?
 Report the actual numbers, even if severity scores are used, to allow readers to cal-
culate rates.
• Use standardized grading for reporting AE severity.
• Follow CONSORT guidelines for reporting harms.
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only 10 of those treated were actually assessed. 4) Use standardized grading criteria for
reporting AE severity. Examples include the National Cancer Institute’s Common Terminol-
ogy Criteria for Adverse Events (available at https://evs.nci.nih.gov/ftp1/CTCAE/About.html)
or the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events
(available at http://rsc.tech-res.com/clinical-research-sites/safety-reporting/daids-grading-
tables). 5) Follow CONSORT guidelines for better reporting of harms in clinical trials [129].
In conclusion, this review has shown that AEs following single dose treatment of LF are
common and should be expected in microfilaremic patients. This information provides a use-
ful context for understanding AEs observed with new treatments for LF. Clear and detailed
reporting of AEs in community treatment studies is essential to accurately inform elimination
program workers and their communities, and to set appropriate expectations. The fear of
MDA-associated AEs is often out of proportion to the actual risk, because most post-treatment
AEs are mild and transient. A frank explanation of AEs as a marker for treatment efficacy by
program managers and community health workers may improve compliance with MDA and
facilitate LF elimination efforts.
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